Universal Beteiligungs und Servicegesellschaft mbH Sells 13,995 Shares of Guardant Health, Inc. $GH

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in Guardant Health, Inc. (NASDAQ:GH) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 287,454 shares of the company’s stock after selling 13,995 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Guardant Health were worth $29,214,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of GH. Emerald Advisers LLC grew its stake in Guardant Health by 24.8% during the third quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock worth $54,558,000 after purchasing an additional 173,281 shares during the period. Knights of Columbus Asset Advisors LLC acquired a new stake in Guardant Health during the third quarter worth approximately $1,554,000. Erste Asset Management GmbH grew its stake in Guardant Health by 10.4% during the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock worth $43,716,000 after purchasing an additional 66,617 shares during the period. Segall Bryant & Hamill LLC grew its stake in Guardant Health by 57.8% during the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock worth $19,066,000 after purchasing an additional 111,822 shares during the period. Finally, TD Asset Management Inc grew its stake in Guardant Health by 16.1% during the third quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock worth $11,797,000 after purchasing an additional 26,210 shares during the period. 92.60% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on GH. Piper Sandler raised their target price on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 24th. TD Cowen raised their target price on Guardant Health from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Raymond James Financial reaffirmed an “outperform” rating and set a $129.00 target price on shares of Guardant Health in a research note on Monday, February 23rd. Barclays decreased their target price on Guardant Health from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Finally, JPMorgan Chase & Co. raised their target price on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Twenty investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $125.20.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $87.87 on Friday. Guardant Health, Inc. has a 52 week low of $36.36 and a 52 week high of $120.74. The stock has a 50 day moving average price of $91.30 and a two-hundred day moving average price of $95.15. The stock has a market capitalization of $11.53 billion, a PE ratio of -26.55 and a beta of 1.64.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same period in the previous year, the business earned ($0.62) earnings per share. The business’s revenue for the quarter was up 39.4% on a year-over-year basis. Research analysts forecast that Guardant Health, Inc. will post -2.87 EPS for the current year.

Insider Transactions at Guardant Health

In related news, insider Terilyn J. Monroe sold 3,832 shares of Guardant Health stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the transaction, the insider owned 20,990 shares of the company’s stock, valued at $1,945,353.20. The trade was a 15.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Musa Tariq sold 348 shares of Guardant Health stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $88.09, for a total value of $30,655.32. Following the transaction, the director directly owned 8,394 shares in the company, valued at approximately $739,427.46. The trade was a 3.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 8,596 shares of company stock worth $775,767. 6.10% of the stock is currently owned by insiders.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.